Farabursen - Novartis
Alternative Names: RGLS-8429Latest Information Update: 28 Jul 2025
At a glance
- Originator Regulus Therapeutics
- Developer Novartis
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action Gene silencing; MIRN17 microRNA expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autosomal dominant polycystic kidney disease
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Autosomal-dominant-polycystic-kidney-disease in USA (SC, Injection)
- 25 Jun 2025 Regulus Therapeutics has been acquired and merged into Novartis
- 08 May 2025 Regulus Therapeutics completes a phase I trial in Autosomal dominant polycystic kidney disease in USA (SC) before May 2025 (NCT05521191)